Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06566716 · ClinicalTrials.gov registry record

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

A clinical trial of Ovarian Neoplasms, sponsored by Cleo Diagnostics.

Recruiting
Registry status
1,000
Enrollment target
8
Study locations

NCT06566716: Recruiting study of Ovarian Neoplasms, sponsored by Cleo Diagnostics.

NCT06566716 is a study of Ovarian Neoplasms that is actively recruiting participants, run by Cleo Diagnostics. The registered enrollment target is 1,000 participants, above the 342-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (192% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06566716, a study of Ovarian Neoplasms, is actively recruiting participants, sponsored by Cleo Diagnostics.

RECRUITING
Registry status
1,000 participants
Enrollment target
8
Study locations

Study Summary

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the current standard test, CA125, in identifying cancer. This study aims to evaluate the effectiveness of the Cleo Diagnostics (CleoDX) Ovarian Adnexal Mass Score Test System. This test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. The test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. By doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.

Conditions Studied

Ovarian Neoplasms

Interventions

  • DIAGNOSTIC_TEST CleoDX ovarian cancer test

Study Locations (8)

Texas

  • Next Innovative Clinical Research - Houston
  • Prime Clinical Research - Lewisville - Lewisville
  • Vast Clinical Research-Holy Cross - Mesquite

Arizona

  • New Horizons Clinical Trials - Chandler

Florida

  • Emerald Coast Clinical Research - Panama City

Nevada

  • Women's Cancer Center of Nevada - Las Vegas

Tennessee

  • The Jackson Clinic - Jackson

Virginia

  • Virginia Women's Health Associates - Annandale

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-09-06
Est. Completion 2026-08
Cleo Diagnostics

1 total trials

What NCT06566716 shows while recruiting

NCT06566716 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 342-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (192% higher).

The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which CleoDX ovarian cancer test is the first listed.

NCT06566716 lists 8 locations in 6 states (Texas, Arizona, Florida).

Frequently Asked Questions

What is clinical trial NCT06566716 about?

NCT06566716 is a clinical study titled "A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass". Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo...

What is the current status of trial NCT06566716?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-09-06. Estimated completion is 2026-08.

What conditions does trial NCT06566716 study?

This clinical trial studies the following conditions: Ovarian Neoplasms.

What interventions are being tested in trial NCT06566716?

The interventions under investigation include: CleoDX ovarian cancer test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06566716?

This trial is sponsored by Cleo Diagnostics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06566716 being conducted?

This trial has 8 study locations across Arizona, Florida, Nevada, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06566716's enrollment target sits among peer trials

1,000 4th of 38 higher than 35 of 38 other Ovarian Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06566716

Source: ClinicalTrials.gov NCT06566716, the US trial registry maintained by the National Library of Medicine. NCT06566716 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.